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FAMILIAL HYPOBETALIPOPROTEINEMIA AND ABETALIPOPROTEINEMIA 
 
JIE CHAN 
 
ABSTRACT 
Familial hypobetalipoproteinemia (FHBL) and abetalipoproteinemia (ABL) are 
rare diseases that cause hypocholesterolemia. Studying FHBL and ABL is 
essential to furthering the field of cholesterol research and has provided many 
therapeutic targets for hypercholesterolemia. ABL is an autosomal, recessive 
disease caused by a mutation in MTP, a chaperone protein in the ER that helps 
fold nascent apoB and transfers lipids onto apoB. FHBL is an autosomal, 
codominant disease caused by a mutation in APOB, which usually causes a 
truncated apoB with loss-of-function. ABL and homozygous FHBL have the same 
clinical symptoms: steatorrhea, neurological dysfunction, vision problems, and 
non-alcoholic fatty liver. Implementing a low-fat diet routine along with vitamin 
supplementations will ameliorate most symptoms except for hepatic steatosis. 
Both ABL and FHBL carry a reduced risk of cardiovascular diseases due to the 
reduction of atherosclerosis. 
 
Many new therapeutic targets for hypercholesterolemia have been inspired by 
FHBL and ABL. Lomitapide is an MTP (microsomal triglyceride transfer protein) 
inhibitor that mimics ABL’s mutant mechanism. Mipomersen is an apoB synthesis 
  vi 
inhibitor, which mimics FHBL’s mutant mechanism. The purpose of both drugs is 
to treat familial hypercholesterolemia. This literature review suggests other 
targets: a molecule to permanently bind apoB to MTP which mimics an FHBL 
mutation, a molecule to prevent PDI from binding to the large M subunit in the 
heterodimer MTP, and a method to truncate apoB to mimic FHBL mutations. Two 
new recently-discovered diseases have similar phenotypes as ABL and FHBL: 
PCSK9 deficiency and familial combined hypolipidemia. Both cause 
hypocholesterolemia. However, PCSK9 does not have the negative systemic 
effects such as steatorrhea and neurological dysfunction. In addition, no fatty 
liver develops. More research into these new diseases can contribute to the field 
of hypocholesterolemia, which provides new therapeutic targets for 
hypercholesterolemia. 
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INTRODUCTION 
 
Plasma cholesterol levels play a major role in determining the quality of our long-
term cardiovascular health. Epidemiology and genetic studies demonstrate that 
plasma low density lipoprotein (LDL) cholesterol levels are directly related to the 
risk of coronary heart disease, and biochemical studies reveal the mechanism 
behind such coronary events (Burnett & Hooper, 2008). A high level of plasma 
LDL cholesterol is associated with an increased risk in myocardial infarctions and 
strokes due to atherosclerosis. Plasma LDL cholesterol is oxidized in the arteries 
and is taken in by macrophages. Once the macrophages are packed with lipid 
vesicles, they are known as foam cells. Accumulation of foam cells within the 
arterial vessel wall forms fatty streaks. This whole process is called 
atherosclerosis. Fatty streaks may progress to an unstable fibrous cap. These 
fibrous caps may unpredictably rupture and form a thrombus, which is a blood 
clot (Burnett & Hooper, 2008). The blood clot may break off and block circulation 
at a further downstream site. Occlusions in circulation lead to heart attack and 
stroke due to oxygen deprivation of cells. Certain drugs can lower plasma LDL 
cholesterol, and clinical trials with these drugs demonstrate a reduction in both 
morbidity and mortality from coronary heart disease (Burnett & Hooper, 2008). 
 
An extremely low level of cholesterol is physiologically is also harmful. 
Hypocholesterolemia is associated with increased morbidity and mortality among 
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many diseases such as sepsis; some doctors consider hypocholesterolemia an 
indicator for such diseases. Critically ill patients may exhibit a severely low level 
of cholesterol. Synthesizing cholesterol is a complex process that demands 
energy, and bodies in physiologically stressful situations may not absorb or 
produce enough cholesterol. Low serum cholesterol may become a potential 
therapeutic target in sepsis among the critically ill (Vyroubal et al., 2008). 
 
Hypocholesterolemia has been hypothesized to be a risk factor for pulmonary 
tuberculosis as well. Patients with tuberculosis often have hypocholesterolemia, 
and many other risk factors for tuberculosis are often associated with 
hypocholesterolemia (Pérez-Guzmán & Vargas, 2006). Cholesterol is vital for a 
healthy immune system and is essential in macrophage uptake and phagocytosis 
of mycobacteria. Clinical trials show that a cholesterol-rich diet may accelerate 
the process of bacteriological sterilization of sputum (Pérez-Guzmán & Vargas, 
2006). 
 
Many factors affect our cholesterol levels such as diet, environment, drugs, and 
genetics. There is much variation in plasma LDL cholesterol levels in the 
population; up to 50% of the variation is due to genetics (Burnett & Hooper, 
2008). Table 1 shows the variation in cholesterol levels in the general population. 
Plasma LDL cholesterol level is considered to be polygenic because many 
different genes at various loci control LDL cholesterol levels. However, a small 
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percentage of the population experience monogenic cholesterol diseases, where 
one gene will affect the cholesterol level drastically. An example of monogenic 
hypercholesterolemia is familial hypercholesterolemia (FH), and examples of 
monogenic hypocholesterolemia are familial hypobetalipoproteinemia (FHBL) 
and abetalipoproteinemia (ABL) (Burnett & Hooper, 2008). 
 
 
Table 1. General population distribution of plasma lipid values and 
apolipoproteins values in mg/dL (Adapted from Kwiterovich Jr, 2013). 
 
 
ApoB-containing 
lipoprotein 
Percentiles 
 
5th 10th 25th 50th 75th 90th 95th 
LDL cholesterol 80 90 110 130 160 180 200 
Non-HDL 
cholesterol 
110 120 140 160 190 210 230 
ApoB 60 70 80 100 80 140 150 
Triglycerides men 46 55 75 112 173 252 324 
Triglycerides 
women 
41 46 50 83 124 182 221 
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This literature review will evaluate the diseases FHBL and ABL in terms of their 
clinical symptoms, current treatment, biochemical mechanisms, and implications 
for future research and studies in cholesterol disease. A brief overview of plasma 
LDL cholesterol metabolism will provide context for understanding the 
biochemical mechanisms in FHBL and ABL. Relating the clinical symptoms to the 
diseases’ biochemical mechanisms will provide insight into current treatment. 
Although FHBL and ABL are rare orphan diseases, FHBL and ABL research 
have provided a wealth of information in treating other more common cholesterol 
dysfunctions such as hypercholesterolemia. Studying FHBL and ABL is a 
necessity that has been indispensable to furthering the field of cholesterol 
research. 
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PLASMA LDL CHOLESTEROL METABOLISM 
 
 
Cholesterol has many important biochemical and physiological functions in the 
body. Cholesterol is a precursor to steroids and biliary acids. Additionally, one 
third of all cell membranes is composed of cholesterol, which provides fluidity 
and flexibility to the structure (Vyroubal et al., 2008). Finally, cholesterol 
participates in cell signaling, particularly in the processes of cell growth and 
phagocytosis. For example, cholesterol plays a crucial role in lymphocytic 
signaling during an immune response (Pérez-Guzmán & Vargas, 2006). 
 
Cholesterol is a hydrophobic compound that cannot travel unaccompanied in 
blood; instead, it needs to be transported in spherical lipoproteins. The core of a 
lipoprotein is hydrophobic while apolipoproteins and polar phospholipids cover 
the surface (Welty, 2014). Other hydrophobic compounds in the core may include 
triglycerides, cholesterol esters, and phospholipids. Apolipoproteins in these 
complexes stabilize the lipid emulsions and also mediate signaling by acting as a 
ligand for receptors on the recipient cells (Burnett & Hooper, 2008). Cholesterol 
from diet is absorbed in the intestines and transported to the liver in chylomicron 
particles. Additionally, cholesterol can be released from the liver in lipoprotein 
complexes and redistributed to peripheral tissues. Figure 1 shows the processes 
of cholesterol absorption and secretion in the intestines and liver. 
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Figure 1. Cholesterol transportation in lipoproteins. Cholesterol is absorbed 
in the intestines and transported to the liver by chylomicrons (CM). VLDL is 
secreted from the liver and eventually becomes metabolized to LDL. The inset 
shows how triglycerides are added to apoB to form VLDL or CM. This is done by 
the chaperone MTP (Taken from Burnett & Hooper, 2008). 
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Different lipoproteins circulate in the blood with cholesterol packed into them: 
very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and 
LDL. They are differentiated by the various apolipoproteins, one of which is 
apolipoprotein B (apoB). ApoB is expressed on lipoproteins made in hepatocytes 
and enterocytes (Lee & Hegele, 2014). It is an amphipathic glycoprotein that is 
required for VLDL and LDL formation (Whitfield, Barrett, Bockxmeer, & Burnett, 
2004).  
 
VLDL synthesis starts in the liver. A nascent apoB without lipids is stabilized by 
microsomal triglyceride transfer protein (MTP) in the hepatocyte’s endoplasmic 
reticulum (ER). ApoB serves as the backbone of VLDL. Then, the chaperone 
MTP transfers lipids to apoB, eventually packing many neutral lipids into the core 
to form a VLDL. A triglyceride-rich lipoprotein, the completed VLDL is secreted 
into circulation by the liver (Burnett & Hooper, 2008). 
 
ApoB synthesized in the liver is different than apoB synthesized in the intestines. 
Enterocytes make a shorter version called apoB-48 while hepatocytes make a 
longer version called apoB-100. Both apoBs are transcribed and translated from 
the same gene, but an mRNA editing process in the intestines causes apoB-48 
to contain only 48% of apoB-100 on the side with the amino terminal. The apoB-
100 RNA in hepatocytes is unedited. Therefore, triglyceride-and-fatty-acid-rich 
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chylomicrons from the intestines contain apoB-48 while VLDL from the liver 
contain apoB-100 (Lee & Hegele, 2014). 
 
Plasma LDL cholesterol levels are influenced by VLDL levels and the activity of 
the liver’s LDL receptors (LDLR) (Burnett & Hooper, 2008). LDL is a metabolic 
product of VLDL. When VLDL is released into circulation, lipoprotein lipase on 
the endothelium hydrolyzes the triglycerides in VLDL. This releases free fatty 
acids, which are then absorbed and used by the peripheral tissues. The remnant 
VLDL is either cleared from circulation or converted into IDL and eventually LDL 
(Kwiterovich Jr, 2013). IDL is either cleared in the liver or is hydrolyzed to LDL by 
hepatic lipase (Kwiterovich Jr, 2013). 
 
ApoB-100 plays a major role in mediating LDL plasma levels. LDL is eventually 
cleared by the liver or oxidized in peripheral tissues. LDL clearance in the liver is 
mediated by LDLR, which recognizes apoB-100 on LDL. Certain mutations in 
apoB result in decreased LDL plasma levels and hypobetalipoproteinemia (HBL). 
Meanwhile, loss of function mutations in LDLR tend to cause increased LDL 
levels and hypercholesterolemia (Burnett & Hooper, 2008). 
 
About 70% of total plasma cholesterol is contained in LDL. Every LDL particle 
has only one apoB that cannot be passed onto other lipoproteins. As a result, the 
number of plasma apoB-100 particles is equal to the number of plasma LDL 
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particles. Therefore, apoB-100 plasma levels are directly related to the incidence 
of coronary heart disease (Burnett & Hooper, 2008). ApoB-100 plays a large role 
in regulating cholesterol plasma levels, which in turn affect the development of 
atherosclerosis, heart attack, and stroke. 
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MONOGENIC HYPOBETALIPOPROTEINEMIAS 
 
Hypobetalipoproteinemia occurs when total serum cholesterol (<150 mg/dL), LDL 
cholesterol (<1.8 mmol/L), or total apoB levels (<50 mg/dL) are less than the 5th 
percentile in a population after adjusting for age, gender, and race (Burnett & 
Hooper, 2008; Harada et al., 2009). There are two forms of HBL: primary and 
secondary. Vegan diet, malnutrition, malabsorption, cachexia, hyperthyroidism, 
severe liver disease, chronic pancreatitis, and certain drugs may cause 
secondary HBL (Whitfield, Barrett, Bockxmeer, & Burnett, 2004). Meanwhile, 
primary HBL is rarer and indicates a genetic origin (Tarugi et al., 2007). Two 
monogenic HBL diseases are familial hypobetalipoproteinemia and 
abetalipoproteinemia. Mutations in APOB cause FHBL, and mutations in MTP 
cause ABL (Tarugi & Averna, 2011). 
 
FHBL can manifest in two forms: heterozygous and homozygous. FHBL 
heterozygotes tend to be asymptomatic (Sen, Dagdelen, & Erbas, 2007). 
However, homozygous hypobetalipoproteinemia (HHBL) presents with the same 
symptoms as ABL (Moutzouri, Elisaf, & Liberopoulos, 2011). HHBL and ABL 
differ in biochemical mechanism due to a difference in the root genetic mutation, 
but they present with the same clinical phenotype with varying severity. Both 
patients are unable to absorb cholesterol from diet or transport cholesterol 
throughout the bloodstream due to a lack of normal apoB (Hooper & Burnett, 
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2014). For both diseases, males and females have the same symptoms. 
Consanguinity is commonly seen in both ABL and HHBL (Lee & Hegele, 2014). 
 
Clinical Symptoms of HHBL and ABL 
 
ABL and HHBL have similar phenotypes and clinical symptoms. Both ABL and 
HHBL patients exhibit steatorrhea, neurological dysfunction, vision problems, and 
non-alcoholic fatty liver (Table 2) (Zamel, Khan, Pollex, & Hegele, 2008). 
However, the severity of symptoms may vary due to different mutations (Lee & 
Hegele, 2014) in APOB for HHBL and MTP for ABL. Generally speaking, ABL 
patients tend to have more severe symptoms than HHBL patients. There is a 
wider range in severity of symptoms among HHBL patients; some patients may 
be asymptomatic while others have severe neurological and gastrointestinal 
issues. Diagnosis of HHBL or ABL is usually determined from a lipid profile, 
blood smear, and clinical symptoms (Lee & Hegele, 2014). Determining the 
difference between HHBL and ABL requires DNA sequencing and/or a family 
history. 
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Table 2. Summary of characteristics in primary HBL (Adapted from Tarugi et 
al., 2007).  
 
Primary 
HBL 
Inheritance Candidate 
gene 
ApoB levels 
compared with 
controls 
Clinical 
characteristics 
FHBL Codominant APOB Reduced (<30%) Homozygotes: 
fatty liver, 
steatorrhea, 
acanthocytosis, 
neurological 
abnormalities 
Heterozygotes: 
asymptomatic, 
fatty liver,  loose 
stools, mild fat 
malabsorption, 
gallstones 
ABL Recessive MTP Absence of 
apoB-containing 
lipoproteins 
Failure to thrive, 
steatorrhea, fat 
malabsorption, 
fatty liver, 
acanthocytosis, 
retinitis 
pigmentosa, 
progressive 
spinocerebellar 
degeneration 
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Laboratory Diagnostics of HHBL and ABL  
 
A lipid profile of absent or very low levels of triglycerides(<0.2 mmol/L), LDL 
cholesterol (<0.1 mmol/L), and apoB (<0.1 g/L) are indicative of HHBL and ABL 
(Lee & Hegele, 2014). Total cholesterol levels are usually less than half of normal 
(often 20-45 mg/dl), and triglycerides are only a few milligrams per deciliter (Sen 
et al., 2007). 
 
Light microscopy of a blood smear will reveal acanthocytosis, which is a 
condition where the red blood cells are anomalously star-shaped (Anoop & 
Parker-Williams, 2009). More than 50% of the circulating erythrocytes may be 
composed of acanthocytes (Figure 2). Anemia may occur as well. The cause of 
acanthocytosis may be due to a lack of iron, folate, and other nutrients secondary 
to fat malabsorption. Additionally, accelerated hydroperoxidation of fatty acids 
may result in hemolysis and anemia (Zamel et al., 2008). 
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Figure 2. Erythrocytes in FHBL and ABL. The top left slide is from a normal 
person. The top right slide is from a FHBL heterozygote with an apoB-40.3 
mutation. The bottom left slide is from a FHBL heterozygote with an apoB-6.9 
mutation. The bottom right slide is from an ABL patient (Taken from Burnett & 
Hooper, 2008). 
 
 
 
 
 
Fat Malabsorption and Fat Soluble Vitamin Deficiencies 
 
Symptoms for ABL and HHBL present during infancy or the first 24 months of life. 
Chronic diarrhea, steatorrhea, and failure to thrive are signs of fat malabsorption. 
Vomiting and abdominal discomfort and distention may occur. However, these 
issues disappear when a low-fat diet is in regimen. When the intestinal epithelium 
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of untreated patients are examined, a “gelee blanche” or “white hoar frosting” 
appears. The enterocytes appear swollen with a clarified cytoplasm full of 
intracellular neutral lipid (Lee & Hegele, 2014). 
 
If patients are diagnosed as adults, neurological and eye problems are the most 
stand-out clinical symptoms (Whitfield et al., 2004). These diagnoses may occur 
later in life because the cases are less severe. Thus, adult patients did not 
present with the typical gastrointestinal symptoms as children. Patients 
diagnosed as adults tend to have retinal degeneration and ataxia in their 20s if 
there has been no treatment or management of the disease (Lee & Hegele, 
2014). 
 
Without early intervention, patients can develop severe conditions including 
typical retinitis pigmentosa, severe ataxia, dysarthria, and absent reflexes. This 
can all lead to a shorter life and intense neurological dysfunction. Early diagnosis 
and treatment can delay or prevent these issues (Whitfield et al., 2004). Without 
intervention, some patients do not live beyond their 30s (Zamel et al., 2008). 
These neurological and retinal issues develop because of a deficiency in fat-
soluble vitamins. 
 
Deficiencies in vitamins A and E generally cause retinitis pigmentosa or retinal 
degeneration with varying severity. Symptoms include loss of night vision and/or 
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color vision (Whitfield et al., 2004). An eye exam may reveal atypical dark 
pigmentation randomly scattered on the retina, which can progress to expanding 
scotomas and blindness. Other less commonly observed eye problems include 
ptosis, ophthalmoplegia, and corneal ulcers (Zamel et al., 2008). Demyelination 
of cranial nerves due to a vitamin E deficiency can cause the first two conditions 
while a deficiency in vitamin A can cause corneal ulcers. Lacrimal glands and 
other ocular tissues depend on vitamin A and its metabolites for normal cell 
functions and growth (Lee & Hegele, 2014). 
 
When both vitamins E and A are supplemented, retinal degeneration still occurs 
though at a reduced rate. The human retina expresses both MTP and apoB, so 
retinopathy could be due to defective inherent proteins rather than a vitamin E 
deficiency (Burnett & Hooper, 2008). 
 
A deficiency in vitamin E can cause neurological problems because 
spinocerebellar axons become demyelinated, which eventually leads to 
immobility. Cerebellar issues occur in forms of ataxia and dysmetria (Pfeiffer, 
2014). The posterior column function may be compromised leading to a loss of 
proprioception and deep tendon reflexes (Burnett & Hooper, 2008). Hyporeflexia, 
reduced vibratory sensation, muscle weakness, peripheral neuropathy, and a 
Friedrich’s-like ataxia are other symptoms (Zamel et al., 2008). Vitamin E 
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supplementation can either delay or prevent these neurological dysfunctions (Lee 
& Hegele, 2014).  
 
Other fat-soluble vitamins may have slight deficiencies, but vitamin E deficiency 
is the greatest. Vitamin E is transported in the circulation by apoB-containing 
lipoproteins. This vitamin is essential for normal neurologic function and 
development. While the other fat-soluble vitamins A, D, and K are reduced in 
concentration in the body, these vitamins have other ways of transportation 
throughout the body. Supplementation with high doses of vitamin E does not 
normalize the vitamin E levels but only raises the levels to 30% of the lower limit 
of normal. Meanwhile, high doses of vitamin A can normalize vitamin A levels. 
Despite transport and absorption issues in the intestines, vitamin A can be 
transported in plasma by retinol-binding protein, which is not damaged in ABL 
and HHBL (Zamel et al., 2008). Some patients are reported to experience 
bleeding tendencies due to a vitamin K deficiency (Aminoff et al., 2012). There 
are documented cases of rickets due to a vitamin D deficiency or secondary 
calcium malabsorption (Hasosah, Shesha, Sukkar, & Bassuni, 2010; Narchi, Amr, 
Mathew, & El Jamil, 2001). 
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Non-Alcoholic Fatty Liver 
 
In ABL and HHBL patients, liver biopsies may reveal hepatocytes with steatosis, 
which is also known as fatty liver. Sometimes, hepatic steatosis is reflected by 
higher serum transaminase levels in a blood sample (Burnett & Hooper, 2008). 
Fatty liver is defined when lipids accumulate in the liver and weigh more than 5% 
of the liver weight (Figure 3). On a light microscopy level, more than 5% of 
hepatocytes contain fatty droplets. Hepatic steatosis appears to be more 
prevalent in HHBL patients than ABL patients (Zamel et al., 2008). The 
mechanism for hepatic steatosis has not been elucidated. One explanation is that 
when apoB is not properly made, the apoB cannot be packed with neutral fatty 
acids while in the hepatocyte. As a result, the fat stays in the liver, and hepatic 
steatosis occurs (Harada et al., 2009). 
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Figure 3. FHBL patient’s liver biopsy. 70-80% of hepatocytes show steatosis 
(Taken from Ballestri et al., 2009). 
 
 
 
Generally, hepatic steatosis is associated with obesity, type-2 diabetes, 
hyperlipidemia, insulin resistance, hypertension, hepatitis, and effects from 
certain drugs and toxins (Sen et al., 2007). However, fatty liver appears to have 
no major negative consequence in the majority of ABL and HHBL patients. 
Studies show that insulin resistance is dissociated from liver steatosis in HHBL 
and heterozygous FHBL  – this suggests that fatty liver is an indication not a 
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cause of metabolic dysfunction (Amaro et al., 2010; Della Corte et al., 2013; 
Visser et al., 2011). 
 
Difference In Genetics Between ABL and FHBL 
 
Both ABL and HHBL have similar symptoms because the diseases have a similar 
root problem; apoB is not properly made or not made at all. However, the cause 
for the mutated apoB is different in ABL and HHBL. ABL is a recessive condition 
that is characterized by a defect in MTP. Meanwhile, FHBL is a codominant 
condition that is characterized by mutations in apoB itself (Lee & Hegele, 2014). 
Heterozygotes with FHBL have low LDL cholesterol levels, a resistance to 
atherosclerosis, and hepatic steatosis; however, they do not have any of the 
other the malignant symptoms. HHBL and ABL are the most severe forms of HBL 
(Burnett & Hooper, 2008). 
 
There are more than 30 mutations described for ABL in the MTP gene while 
there are more than 60 mutations described in the literature for FHBL in the 
APOB gene (Lee & Hegele, 2014).  
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Heterozygotes with FHBL 
 
FHBL is the most frequent monogenic form of HBL. FHBL is caused by a loss-of-
function mutation in the APOB gene, usually resulting in a truncated apoB protein 
(Tarugi et al., 2007). FHBL for both heterozygotes and homozygotes is 
associated with protection against atherosclerosis and has a prevalence of 
1:3000. It is an autosomal codominant disorder (Burnett & Hooper, 2008). The 
heterozygous form is estimated to be found 1:500-1:1000 (Aminoff et al., 2012). 
 
Heterozygotes with FHBL are generally asymptomatic or may have mild 
symptoms; however, they generally have hepatic steatosis. Their plasma LDL-
cholesterol levels and apoB concentrations are usually below the 50th percentile 
(Hooper & Burnett, 2013). LDL and apoB concentrations are generally one fourth 
to one third of the normal concentration (Burnett, Bell, Hooper, & Hegele, 2012b). 
Total cholesterol levels range from 40-180 mg/dl with the average around 
90mg/dl. LDL concentrations are 25-45 mg/dl or less than 50% of the average. 
ApoB levels are still very low (Sen et al., 2007). 
 
FHBL heterozygotes can be differentiated from ABL carriers. FHBL 
heterozygotes exhibit low levels of apoB and LDL-cholesterol while ABL carriers 
have normal lipid profiles. This is consistent with the inheritance patterns (Lee & 
Hegele, 2014). 
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With low circulating plasma LDL levels, heterozygotes have a reduced risk of 
coronary heart disease, and their lifespan is thought to increase by 10 years on 
average. Their arterial walls exhibit less stiffness, which is indicative of 
cardiovascular protection (Burnett et al., 2012b). However, FHBL heterozygotes 
may still develop fatty liver. Serum liver enzymes ALT, AST, and GGT may be 
raised (Burnett & Hooper, 2008). Sometimes, oral fat intolerance and intestinal 
fat malabsorption may be reported (Tarugi et al., 2007). Acanthocytes are 
sometimes observed in heterozygous FHBL blood samples (Burnett & Hooper, 
2008). 
 
Heterozygotes are predicted to live a normal lifespan. There is no specific 
treatment for heterozygotes, but moderate supplements of vitamin E are 
sometimes recommended, even though neurological problems rarely occur in 
heterozygotes. When compared to homozygotes, heterozygotes rarely develop 
liver pathologies, but periodic clinical and lab examination are still recommended. 
Genetic counseling is recommended as well (Sen et al., 2007). 
 
Genetics of ABL 
 
ABL is due to a rare, autosomal, monogenic recessive mutation in MTP 
(“Abetalipoproteinemia,” n.d.). MTP is a chaperone protein that helps add lipids 
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to apoB in the ER of hepatocytes and enterocytes (Tarugi et al., 2007). MTP is a 
heterodimer composed of a unique large subunit M and protein disulfide 
isomerase (PDI). Mutations in the large subunit M of MTP can cause an absence 
of MTP in ABL patients. MTP is essential for assembly and secretion of apoB 
from the liver and intestines (Gregg & Wetterau, 1994). In ABL patients, there are 
no apoB-containing lipoproteins in serum (Lee & Hegele, 2014). ApoB cannot be 
synthesized, so there is no LDL and VLDL in the blood (Aminoff et al., 2012). 
Patients with ABL have coronary arteries that are free of atherosclerotic lesions 
(Zamel et al., 2008). Lipid profiles for an ABL patient include severely low plasma 
levels of total cholesterol, VLDL, LDL, and nearly no apoB at all (Tarugi et al., 
2007). Meanwhile, ABL carriers have normal plasma lipid levels (Tarugi et al., 
2007). 
 
Abetalipoproteinemia is a rare metabolic disease with approximately 100 cases 
described worldwide (“Abetalipoproteinemia,” n.d.). Others estimate ABL to occur 
in 1:100,000 to 1:1,000,000 (Burnett, Bell, Hooper, & Hegele, 2012a; Zamel et al., 
2008). Other names for ABL include abetalipoproteinemia neuropathy, 
acanthocytosis, apolipoprotein B deficiency, Bassen-Kornzweig Syndrome, 
Betalipoprotein deficiency disease, congenital betalipoprotein deficiency 
syndrome, and microsomal triglyceride transfer protein deficiency disease 
(“Abetalipoproteinemia,” n.d.). 
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Current Treatment for Both ABL and FHBL 
 
Treatment and management for both diseases involve a strict low-fat diet along 
with supplementation of essential fatty acids. High oral doses of fat soluble 
vitamins are given as well. Prognosis with treatment is generally excellent but 
may vary, and early diagnosis and treatment can reverse some neurological 
damage and stop neurological dysfunctions from progressing (Lee & Hegele, 
2014). Nutritionists, lipidologists, gastroenterologists, hepatologists, 
ophthalmologists, and neurologists may be involved in the patient’s treatment 
plan (“Abetalipoproteinemia | Disease | Overview | Office of Rare Diseases 
Research (ORDR-NCATS),” n.d.). 
 
Restriction of long-chain fatty acids prevents fat malabsorption and steatorrhea. 
Fat intake is restricted to 5-20 g/day, which prevents steatorrhea and accelerates 
growth (Kwiterovich Jr, 2013). Linoleic acid supplements such as 5 g corn oil or 
safflower oil/d may be given. Medium chain triglycerides (MCTs) as a dietary 
supplement may be an alternate for a fat source in diet because lipids are 
necessary for normal growth and development. MCTs are absorbed differently 
than other fats, which can prevent the intestinal discomfort (Schonfeld, Lin, & 
Yue, 2005). However, some say that MCTs may produce hepatic fibrosis, so they 
should be used cautiously if at all (Zamel et al., 2008). 
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High doses of fat-soluble vitamins are given orally as water emulsions. This 
process sidesteps the intestinal chylomicron assembly pathway via the portal 
circulation, so these vitamins can be absorbed. High dose oral vitamins A, E, and 
K are given. Moderate supplementation of vitamin E concentrations is 
recommended in those with heterozygous FHBL to prevent neurological 
problems (Burnett et al., 2012b). Injectable vitamins are also an option (Zamel et 
al., 2008). Oral Vitamin E is given in daily doses ranging from 2400 to 12000 IU 
(Zamel et al., 2008). Table 3 shows the overall diet plan for patients with ABL 
and HHBL. 
 
Table 3. Summary of diet management of ABL and HHBL (Taken from Lee & 
Hegele, 2014). 
General -Ensure adequate caloric intake 
Lipids 
-Low fat (<30 % of total calories), with reduced long-chain fatty acids 
-Oral essential fatty acids 
-Medium chain triglycerides generally unnecessary 
Vitamins 
-Oral fat-soluble vitamins: 
-Vitamin E 100–300 IU/kg/day 
-Vitamin A 100–400 IU/kg/day 
-Vitamin D 800–1200 IU/day 
-Vitamin K 5–35 mg/week 
 
 
 
 
There are no current treatments for non-alcoholic fatty liver (Schonfeld et al., 
2005). While the hepatic steatosis appears to be mostly harmless, studies 
indicate that any additional slight hepatic damage will induce and stimulate 
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fibrosis (Ballestri et al., 2009). There are reported cases where exercise may be 
effective in controlling macrovesicular steatosis (Harada et al., 2009).  
 
There are no specific medications and standardized treatment plan for ABL and 
HBL; each case is managed with specific diet changes that work well for the 
individual (Lee & Hegele, 2014). See Tables 4 and 5 for general follow-up 
protocol for ABL and HHBL. 
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Table 4. ABL and HHBL general follow-up plan after diagnosis (Taken from 
Lee & Hegele, 2014). 
Clinical evaluation – every 6–12 months Laboratory investigations – every year 
General • Height/weight for growth curve Lipids* • total cholesterol 
   
• triglyceride 
   
• LDL-C 
Diet • Adequate caloric intake 
 
• HDL-C 
 
• Low-fat (<30 % total calories) 
diet with EFA supplements  
• apo B 
 
• MCTG intake generally not 
required  
• apo A1 
 
• Vitamin supplementation Hepatic • AST 
GI • Appetite 
 
• ALT 
 
• Diarrhea 
 
• GGT 
 
• Vomiting 
 
• Total and direct 
bilirubin 
 
• Esophagitis 
 
• ALP 
 
• Abdominal distention 
 
• Albumin 
 
• Hepatomegaly Vitamins • Beta-carotene 
Neurological • Expected development for age 
 
• 25-OH vitamin D 
 
• Ataxia 
 
• Plasma or RBC 
vitamin E 
 
• Dysarthria 
 
• INR 
 
• Hyporeflexia Other • CBC 
 
• Proprioception loss 
 
• Vitamin B12 
 
• Muscle pain or weakness 
 
• Folate 
   
• Calcium 
   
• Phosphate 
   
• Uric acid 
   
• Thyroid stimulating 
hormone 
 
Abbreviations: EFA, essential fatty acid; MCTG, medium chain triglyceride; LDL-C, low density 
lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; apo, apolipoprotein; AST, 
aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutamyl transferase; 
ALP, alkaline phosphatase; RBC, red blood cell; INR, international normalized ratio; CBC, 
complete blood count; DXA, dual energy X-ray absorptiometry 
*lipid profile should absolutely be performed at baseline, however yearly follow-up is not 
absolutely essential as these levels typically remain stable over the long term 
 
  
 28 
Table 5. ABL and HHBL general follow-up labs and examinations after 
diagnosis (taken from Lee & Hegele, 2014). 
 
Additional investigations: Age > 10 Years 
Hepatic ultrasonography Every 3 years 
Neurological examination Every 6–12 months 
Ophthalmological examination Every 6–12 months 
Bone mineral density via DXA Every 3 years 
Echocardiography Every 3 years 
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BIOCHEMISTRY OF ABL AND FHBL MUTATIONS 
 
The biochemistry behind ABL and FHBL mutations provides context for 
understanding the clinical presentation of ABL and FHBL. An explanation for the 
range of severity in FHBL symptoms can be explained biochemically. Additionally, 
the mechanisms behind each disease can provide research leads for future drug 
treatments in ABL and FHBL. The unique mutations in ABL and FHBL may 
provide insight into other cholesterol diseases such as familial 
hypercholesterolemia and inspire new ideas for treatment.  
 
ABL Mutations Biochemistry 
 
Loss of function mutations in the microsomal triglyceride transfer protein cause 
ABL. MTP is a chaperone protein in the ER that helps fold nascent apoB and 
also transfers lipids onto the newly synthesized apoB (Ohashi et al., 2000). MTP 
is a heterodimer composed of a large subunit M and a common enzyme called 
protein disulfide isomerase PDI (Figure 4) (Shoulders et al., 1993). The M 
subunit is an 894 amino-acid 97 kDa protein. The MTP gene is located on 
chromosome 4q22-24 (Aminoff et al., 2012). 
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Figure 4. Predicted structure of MTP. Four missense mutations are highlighted 
(Taken from Aminoff et al., 2012). 
 
 
  
MTP has three major domains: N-terminal beta barrel domain (residues 22–297), 
middle alpha helical domain (residues 298–603), and the C-terminal domain 
(residues 604–894). The beta barrel domain facilitates MTP’s binding with the 
amino terminus of apoB while the alpha helical domain binds MTP to PDI and 
apoB (Hussain, Rava, Walsh, Rana, & Iqbal, 2012). These two domains are both 
globular and are homologous to another ancient protein vitellogenin, which is an 
apolipoprotein in egg laying animals. Meanwhile, the C-terminal domain is 
responsible for the lipid-binding enzymatic activity of MTP (Zamel, Khan, Pollex, 
& Hegele, 2008). Amino acids 666-736 in the C-terminal domain are homologous 
to amino acids 389-584 in cholesteryl ester transfer protein (Aminoff et al., 2012). 
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This suggests that certain lipid transferring activities are conserved across lipid-
transfer enzymes. 
 
MTP mutations can misfold apoB and thus produce a non-functional or non-
existent lipoprotein. Additionally, a mutated MTP may be unable to enzymatically 
transfer lipids to apoB due to a mutation in enzymatic function. In ABL, no VLDL 
is secreted due to a defective apoB (Lee & Hegele, 2014). Without MTP and 
lipids, the nascent apoB is rapidly degraded; Figure 5 (Aminoff et al., 2012).  
 
 
 
Figure 5. VLDL formation. First, apoB is translated. In conditions lipid-free MTP, 
apoB is transferred to the cytosol and degraded intracellularly. In conditions with 
MTP and lipids, triglycerides are packed into the center with apoB on the surface 
(Taken from Whitfield et al., 2004). 
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PDI is essential for the MTP complex function, but there are no reports of ABL 
with mutations in PDI (Wang & Hegele, 2000). Missense mutations in MTP can 
interfere with PDI binding, which again indicates the importance of PDI in the 
MTP complex (Burnett & Hooper, 2008). The purpose of PDI seems to be to 
stabilize the MTP complex because PDI is not involved in any of MTP’s 
enzymatic activities. PDI’s inherent enzymatic activities are not involved with 
MTP’s enzymatic activities either (Hussain et al., 2012). 
 
Mutations in MTP in ABL patients usually feature a truncated protein devoid of 
function. Some other missense mutations have been reported along with less 
severe symptoms (Tarugi et al., 2007). However, in general, there is uncertainty 
regarding a relationship between MTP genotype and severity of symptoms (Lee 
& Hegele, 2014; Wang & Hegele, 2000). More than 30 mutations in MTP have 
been found. The majority are small point mutations (missense, nonsense, and 
splicing) that cause splicing errors or premature truncations throughout the 
gene’s 18 exons (Figure 6). MTP missense mutations may prevent the M subunit 
from binding with PDI or apoB. If binding does occur, the mutation may prevent 
MTP from transferring lipids into apoB (Burnett & Hooper, 2008). Most of these 
mutations are contained within families or ethnic communities (Burnett, Bell, 
Hooper, & Hegele, 2012a).
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FHBL Mutations Biochemistry 
 
Loss-of-function mutations in APOB cause FHBL; more than 60 mutations in 
APOB have been found that cause FHBL. The APOB gene is located on 
chromosome 2 (Harada et al., 2009). Most mutations that cause FHBL are point 
mutations that cause splicing errors or premature truncations (Lee & Hegele, 
2014). Missense, nonsense, and frameshift splicing mutations in the 29 exons of 
APOB can lead to truncated forms of apoB (Figure 7). The most common type of 
mutations for FHBL are missense mutations in the amino terminal region (Burnett 
et al., 2012b).  
 
 
 
 
Figure 7. Selected FHBL mutations in the 29 exons of APOB. Many 
mutations are located in exon 26 and are composed of nonsense and frameshift 
mutations (Taken from Whitfield, Barrett, Bockxmeer, & Burnett, 2004). 
 
 
The degree of truncation is directly related to the severity of symptoms in FHBL. 
ApoB-100 is the largest apolipoprotein with 4,536 amino acids. Truncation 
mutations can result in proteins as short as apoB-2 (2% of full length apoB-100) 
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or as long as apoB-89 (89% of full length apoB-100).The shorter the truncation, 
the smaller the number of triglyceride molecules that the apoB can transport (Sen 
et al., 2007). HHBL patients with apoBs shorter than apoB-48 have the same 
clinical phenotype as ABL patients. Meanwhile, HHBL patients with longer apoB 
truncations may have fatty liver as the only symptom of the disease (Lee & 
Hegele, 2014). A truncated apoB shorter than 54.5 is a risk factor for developing 
fatty liver (Sen et al., 2007). HHBL patients with mutations longer than apoB-48 
have milder symptoms than HHBL patients with shorter mutations (Burnett et al., 
2012b). 
 
HHBL patients with the most severe phenotype have truncated apoBs smaller 
than apoB-30 (Lee & Hegele, 2014). Heterozygotes with apoB mutations shorter 
than apoB-48, may only have fatty liver and mild fat absorption. Meanwhile, 
homozygotes with long truncations like apoB-87 are asymptomatic or may just 
have fatty liver (Burnett et al., 2012b).  
 
Mutated apoBs larger than apoB-29 can be detected in plasma by Western blot 
analysis; however shorter truncations are not detectable in plasma and can only 
be identified by DNA sequencing. Shorter apoBs cannot acquire enough lipids for 
a hydrophobic core, so they are degraded intracellularly (Burnett & Hooper, 
2008). The C terminus of apoB-37 and the C terminus of apoB-42 regulate 
apoB’s intracellular stability and the secretion of apoB from the liver. In vitro 
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studies show that the initial 884 amino acids on apoB are required for apoB and 
MTP binding. Therefore, the smallest form of apoB to bind to MTP would be 
apoB-19.5 (Whitfield et al., 2004).  
 
The apoB secretion rate from the liver is related to the amount of truncation – 1.4% 
reduction in secretion rate for each 1% of apoB truncated. Smaller apoBs are 
produced at a slower rate than apoB-100; however, the smaller apoBs are 
cleared from circulation faster than apoB-100 (Whitfield et al., 2004). For 
example, apoB-89 is produced 15% more slowly than apoB-100, and apoB-89 
lipoproteins are cleared twice as fast as apoB-100 lipoproteins. Lacking the 
carboxy terminal of apoB increases the affinity for LDLR. Truncations smaller 
than apoB-70.5 are cleared extremely fast by the kidneys (Schonfeld et al., 2005).  
 
Other mutations in APOB exist outside of truncation mutations. Certain mutations 
near the N terminal of apoB can increase binding to MTP, which will eventually 
cause misfolding of apoB due to too tight of a binding. ApoB’s βα1 domain near 
the N-terminal interacts with MTP; Figure 8. Two mutations L343V and R463W 
occur in this region, which result in a low-cholesterol phenotype for 
heterozygotes. L343 and R463 are conserved among other mammals, which 
suggests these particular residues are important (Burnett & Hooper, 2008). 
Mutations L343V and R463W impair secretion of apoB-100 and VLDL in in vitro 
studies. There is increased ER retention of apoB and increased apoB binding to 
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MTP and BiP, which is another general chaperone protein. These mutations alter 
the folding of the alpha helical domain in the N terminus of apoB (Burnett & 
Hooper, 2008). 
 
 
 
 
 
 
Figure 8. ApoB-100 gene and apoB five structural domains. The domains are 
labeled from left to right: beta alpha 1, beta 1, alpha 2, beta 2, and alpha 3. The 
site of cleavage to form apoB-48 is shown by the arrow (Taken from Whitfield et 
al., 2004). 
 
 
At the other end of the apoB protein, the carboxy terminal regulates LDLR uptake. 
A lack of the carboxy terminus in apoB-100 results in better LDLR binding thus 
better LDL uptake and clearance from plasma (Burnett & Hooper, 2008). 
Mutations in APOB affecting the LDLR binding domain like R3527Q are 
associated with hypercholesterolemia, the opposite phenotype of FHBL. LDL 
cholesterol and apoB are double the normal levels (Lee & Hegele, 2014). Defects 
in the carboxy terminus of the LDLR binding domain of apoB cause familial 
ligand-defective apoB-100, a form of autosomal dominant hypercholesterolemia 
(Whitfield et al., 2004). 
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DISCUSSION 
 
There are no discussions in the literature regarding the search for a biochemical 
cure for FHBL and ABL. Currently both diseases are clinically managed with diet 
changes and vitamin supplements. Both diseases have excellent prognoses 
once the proper dietary regimen is established. FHBL and ABL are manageable 
conditions that do not seem to have a significant decrease in quality of life with 
treatment. As a result, there is no need to explore risky treatment options in gene 
therapy or other drastic medications when a low-fat diet with vitamin replacement 
therapy is sufficient to treat the symptoms. However, depending on coexisting 
risk factors and conditions, hypothesizing other methods of curing FHBL and ABL 
may lead to insights that have real world application in this or other cholesterol 
diseases. 
 
For both diseases, replacing the defective MTP or apoB with a working protein is 
one curative method. Gene therapy could place a functional MTP or apoB back 
into the hepatocyte or enterocyte. Enzyme or protein replacement therapy could 
work as well. Lipoproteins could be directly infused into the patient to increase 
LDL cholesterol in the plasma. While many of these ideas would be expensive 
and thus a cost analysis would be needed, the basic idea of placing the normal 
MTP or apoB back in the body is worthwhile. There would be no need to delete 
the mutated versions due to the recessive inheritance pattern of ABL and the 
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codominant inheritance pattern of FHBL. Both the mutated and normal versions 
could co-exist with a normal phenotype. Such treatments could help determine 
threshold levels of MTP and apoB required for a normal phenotype and lead to 
questions such as how much normal MTP needs to exist to override the effects 
of the mutated MTP? These threshold studies could have implications in the 
future design of cholesterol-lowering drugs. How much of mutated MTP is 
needed to turn off the effects of normal MTP is another intriguing question. Lastly 
elucidating the inheritance pattern of FHBL and ABL can provide further clues as 
to how to properly dose cholesterol-lowering drugs. 
 
FHBL and ABL are unique diseases in that the disease mutations themselves 
have inspired treatment for other cholesterol diseases. Recently, two drugs are in 
the process of clinical trials to treat familial hypercholesterolemia: Lomitapide and 
Mipomersen. Lomitapide is an MTP inhibitor, which mimics ABL (Davis & 
Miyares, 2014). Mipomersen is an apoB synthesis inhibitor, which mimics FHBL 
(Thomas et al., 2013). Studying the biochemistry in FHBL and ABL can provide 
other therapeutic targets for hypercholesterolemia. 
 
Perhaps another therapeutic target for hypercholesterolemia is a molecule that 
permanently attaches apoB to MTP. One FHBL mutation in apoB causes 
increased binding to MTP thus resulting in less VLDL secretion and greater apoB 
retention in hepatocytes. If a medication could permanently bind apoB to MTP 
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thus preventing lipoprotein formation, LDL levels could be reduced. However, a 
side effect and risk of this mechanism is fatty liver because FHBL patients with 
this mutation have non-alcoholic fatty liver.  
 
Another potential therapeutic target for FH is PDI. MTP requires both the large M 
subunit and PDI to form a working MTP complex – MTP would not be able to 
function without proper binding to PDI. Perhaps a molecule could be made to 
prevent MTP heterodimer formation by targeting PDI. Without MTP, lipids cannot 
be added to apoB and lipoproteins cannot be made. 
 
ApoB truncation could be a method of treating hypercholesterolemia. The 
severity of symptoms in HHBL is directly related to the amount by which apoB is 
truncated; the greater the truncation, the more severe the symptoms. Patients 
with longer truncated apoBs such as apoB-89 are generally asymptomatic yet 
appear to have all the cardiovascular benefits. A future cholesterol-lowering 
medication could incorporate the idea of truncating apoBs to lower plasma LDL 
cholesterol. Stopping the transcription or translation of apoB earlier can form a 
truncated protein such as apoB-89. Hypobetalipoproteinemia could be induced 
except without all the negative symptoms. 
 
The interaction of “opposite” mutations on apoB may provide useful information 
for future drug treatments in hypocholesterolemia and hypercholesterolemia. 
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Except for the truncation mutations that delete parts of apoB, most apoB 
mutations that cause FHBL are near the N terminus while mutations on the 
carboxy terminus cause hypercholesterolemia. What happens when both 
mutations are present? The FHBL mutation would interfere with MTP binding 
thus releasing less VLDL and LDL into circulation; on the other hand, a mutation 
that decreases LDLR affinity on the carboxy terminus would allow the meager 
amount of VLDL and LDL to circulate for an even longer period of time. The 
secretion rate for apoB would not change, but the clearance rate would be 
decreased. Over time, would LDL levels build up? Would the two mutations 
cancel out each other and thus produce a normal phenotype?  Studies into 
questions such as these may provide valuable information for future therapeutic 
designs.  
 
More research into apoB intracellular degradation in hepatocytes could help find 
new therapeutic targets in cholesterol lowering medication. It is known that in 
FHBL patients, truncated apoBs that are too short to bind to MTP end up being 
degraded intracellularly. Studying this mechanism in detail might reveal a way to 
degrade apoB proteins before binding with MTP. If so then a medication could 
tag apoB for degradation and be utilized as another approach to treat 
hypercholesterolemia.  
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Studies in FHBL and ABL have led to insights in other diseases. For example, 
one symptom of FHBL and ABL that has already been of interest to many 
researchers is the non-alcoholic fatty liver. FHBL and ABL helped show that fatty 
liver is dissociated from insulin resistance. This shows the importance of studying 
rare diseases that already have excellent management plans; such diseases 
may play roles in other diseases or help elucidate processes in other diseases. 
 
Recently, new mutations in different genes that display a similar clinical 
phenotype as FHBL have been identified. Nonsense mutations in proprotein 
convertase subtilisin kexin type 9 (PCSK9) have been associated with 
hypocholesterolemia as well, but these mutations do not have the same systemic 
symptoms such as steatorrhea and conditions caused by fat-soluble vitamin 
deficiencies  (Burnett & Hooper, 2008). PCSK9 is a serine protease that 
degrades LDLR and regulates the number of LDLRs in the liver – inactivation of 
PCSK9 causes more LDLRs and thus more LDL uptake from plasma thus 
resulting in hypobetalipoproteinemia (Harada et al., 2009). Homozygous PCSK9 
deficiency is a rare condition, more so than ABL and FHBL, and is autosomal 
codominant. Loss-of-function mutations are more common in PCSK9 than gain-
of-function mutations (Burnett & Hooper, 2008). Heterozygotes have lower 
plasma LDL cholesterol levels and plasma apoB, and homozygotes do not have 
as low of LDL and apoB as ABL and HHBL. No fatty liver developments occur in 
carriers of the PCSK9 loss-of-function mutation (Burnett, Bell, Hooper, & Hegele, 
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2012; Lee & Hegele, 2014; Tarugi et al., 2007). Studying homozygous PCSK9 
deficiency could lead to other therapeutic targets in lowering cholesterol. 
 
Another condition with a similar clinical phenotype as HHBL and ABL is familial 
combined hypolipidemia. Familial combined hypolipidemia is another rare 
condition with extremely low but not absent levels of apoB-containing lipoproteins. 
This is due to homozygous mutations in angiopoietin-like protein 3 ANGPTL3. 
Both PCSK9 deficiency and familial combined hypolipidemia are only present in 
a few number of families in the world (Burnett et al., 2012). More research is 
necessary in these rare diseases to better understand how LDL levels are 
manipulated, which can provide future therapeutic targets in lowering cholesterol. 
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CONCLUSION 
 
Although cholesterol levels are considered to be polygenic, monogenic 
cholesterol diseases can drastically change a person’s cholesterol levels. ABL 
and FHBL are monogenic diseases of hypobetalipoproteinemia, which is defined 
as having total cholesterol, LDL cholesterol, or total apoB levels below the 5th 
percentile in a population after adjusting for age, gender, and race.  ABL is a 
rare, autosomal, recessive disease caused by a mutation in MTP. FHBL is a rare, 
autosomal, codominant disease caused by a mutation in APOB. ABL and HHBL 
have the same clinical symptoms: steatorrhea, neurological dysfunction, vision 
problems, and non-alcoholic fatty liver. Patients have very low or absent apoB 
and LDL cholesterol. Neurological and retinal problems are caused by a 
deficiency in the fat-soluble vitamins. Implementing a low-fat diet routine along 
with vitamin supplementations will ameliorate most symptoms except for hepatic 
steatosis. Heterozygous FHBL is generally asymptomatic or may present with 
mild symptoms with low apoB and cholesterol levels. Both ABL and FHBL cause 
a reduced risk in cardiovascular diseases. 
 
ABL is caused by mutations in MTP, which is a chaperone protein in the ER that 
helps fold nascent apoB and then transfers lipid onto apoB. MTP is a 
heterodimer composed of a large subunit M and PDI. All mutations occur in the 
M subunit. A defective MTP either cannot fold or cannot transfer lipids to apoB, 
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which ends up being rapidly degraded. No VLDL is secreted from the liver. There 
is uncertainty regarding a relationship between MTP genotype and severity of 
symptoms. 
 
FHBL is caused by loss-of-function mutations in APOB. Most mutations produce 
a truncated apoB, and a few mutations include missense mutations in the amino 
terminal region. In HHBL, severity of symptoms is directly related to the degree of 
truncation. Homozygotes with long truncations like apoB-87 are asymptomatic or 
may only have hepatic steatosis while homozygotes with short truncations like 
apoB-48 have severe symptoms. A few FHBL mutations cause increased binding 
to MTP; apoB is eventually misfolded, and VLDL is not secreted from the liver.  
 
Studying FHBL and ABL contributes to finding new therapeutic targets for 
hypercholesterolemia. Lomitapide is an MTP inhibitor that mimics ABL’s mutant 
mechanism. Mipomersen is an apoB synthesis inhibitor, which mimics FHBL’s 
mutant mechanism. The purpose of both drugs is to treat familial 
hypercholesterolemia. Other suggested targets include a drug used to 
permanently bind apoB to MTP, which mimics an FHBL mutation. This way, no 
apoB and VLDL can be released from the hepatocyte. Preventing PDI from 
binding to the large M subunit is another target. ApoB truncation is another 
mechanism to lower cholesterol – HHBL patients with longer truncated apoBs 
such as apoB-89 are generally asymptomatic yet receive all the cardiovascular 
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benefits. Additionally, studying how truncated apoBs are degraded might be 
another approach to treat hypercholesterolemia. 
 
Two new diseases with similar phenotypes as ABL and FHBL are homozygous 
PCSK9 deficiency and familial combined hypolipidemia. PCSK9 deficiency 
causes hypocholesterolemia as well but does not cause the negative systemic 
effects such as steatorrhea and neurological dysfunction. No fatty liver develops 
either. Familial combined hypolipidemia is caused by homozygous mutations in 
ANGPTL3. More research into PCSK9 and ANGPTL3 can contribute to the field 
of hypocholesterolemia, which can give new leads in finding new cholesterol-
lowering medication. 
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